Trials that use: Exact / Clopper-Pearson binomial
New to this method? Read the tutorial →
1,265 results
- FX-322 in Sensorineural Hearing Loss: Complete Statistical AnalysisIndependent statistical analysis of FX-322 in Sensorineural Hearing Loss: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03616223).
- G-BMTIndependent statistical analysis of Buprenorphine Group Medical Visits in Primary Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02526212).
- G-Pen™ for Hypoglycemia Rescue in T1D Patients: Complete Statistical AnalysisIndependent statistical analysis of G-Pen™ for Hypoglycemia Rescue in T1D Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02423980).
- GALATHEAIndependent statistical analysis of the phase 3 GALATHEA trial of benralizumab 30 mg and 100 mg versus placebo in moderate to very severe COPD with exacerbation history, covering negative binomial exacerbation-rate ratios,…
- GALAXYIndependent statistical analysis of Long-term Evaluation of the Linox Family ICD Leads Registry (GALAXY): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00836589).
- GAM 10-06Independent statistical analysis of Non-Interventional Study on the Tolerability and Efficacy of IVIG: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02303093).
- Gardasil Vaccination in Post Stem Cell Transplant Patients: Complete Statistical AnalysisIndependent statistical analysis of Gardasil Vaccination in Post Stem Cell Transplant Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01092195).
- GARGLESIndependent statistical analysis of Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval, sample-size…
- Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval,…
- Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01459614).
- Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) – Retinitis Pigmentosa GTPase Regulator (RPGR): Complete Statistical AnalysisIndependent statistical analysis of Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy: Complete Statistical AnalysisIndependent statistical analysis of Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas: Complete Statistical AnalysisIndependent statistical analysis of Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream: Complete Statistical AnalysisIndependent statistical analysis of Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Global Prospective Case Series Using a Single-Use Duodenoscope: Complete Statistical AnalysisIndependent statistical analysis of Global Prospective Case Series Using a Single-Use Duodenoscope: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04103749).
- GLS-5700 in Dengue Virus-Naïve Adults: Complete Statistical AnalysisIndependent statistical analysis of GLS-5700 in Dengue Virus-Naïve Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02809443).
- GO-COLITISIndependent statistical analysis of Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02092285).
- Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA): Complete Statistical AnalysisIndependent statistical analysis of Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.: Complete Statistical AnalysisIndependent statistical analysis of GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV)…
- Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- GVHD ASEDIndependent statistical analysis of A Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients: primary endpoint results,…
- HALO Patient Registry: Ablation of Barrett’s Esophagus: Complete Statistical AnalysisIndependent statistical analysis of HALO Patient Registry: Ablation of Barrett's Esophagus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00848237).
- Hand-carried Ultrasound to Assess Hydronephrosis: Complete Statistical AnalysisIndependent statistical analysis of Hand-carried Ultrasound to Assess Hydronephrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03774719).
- HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02232243).
- HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC): Complete Statistical AnalysisIndependent statistical analysis of HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01849588).
- HDIL2/EmendIndependent statistical analysis of Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- HEAL-LAAIndependent statistical analysis of HEAL-LAA Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05809596).
- Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic: Complete Statistical AnalysisIndependent statistical analysis of Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- HELPS-HDIndependent statistical analysis of Health Effects of oraL Protein Supplements in HD (The HELPS-HD Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine: Complete Statistical AnalysisIndependent statistical analysis of Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine: primary endpoint results, effect estimate…
- Hepatitis B Booster Study in Adolescence: Complete Statistical AnalysisIndependent statistical analysis of Hepatitis B Booster Study in Adolescence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02169674).
- High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin’s Lymphoma or Central Nervous System (CNS) Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Complete Statistical AnalysisIndependent statistical analysis of High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): primary endpoint results, effect estimate with confidence interval, sample-size…
- High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00349778).
- High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- HIPCVAX-010SIndependent statistical analysis of Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Home-based Delivery of the Contraceptive Implant in Postpartum Guatemalan Women: Complete Statistical AnalysisIndependent statistical analysis of Home-based Delivery of the Contraceptive Implant in Postpartum Guatemalan Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04005391).
- HOPE-2-OLEIndependent statistical analysis of Open-label Extension of the HOPE-2 Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04428476).
- Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- HRVIndependent statistical analysis of Heart Rate Variability in Trauma Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00795535).
- HSCT for High Risk Inherited Inborn Errors: Complete Statistical AnalysisIndependent statistical analysis of HSCT for High Risk Inherited Inborn Errors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00383448).
- HSIIndependent statistical analysis of Home Safety Intervention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06216327).
- HUCSIndependent statistical analysis of Human Use Condition Study- Evaluation of Implanted Leads in Humans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04320849).
- Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules: Complete Statistical AnalysisIndependent statistical analysis of Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…